Members

The aim of Micar21 is to provide urgently high quality data about the effect of the Next Covid-19 mutations.

We want to provide example of science validation of the capability and speed of Micar21 Drug Discovery Platform, which can be viewed and validated through science publications. Early of December no one had accurate data on the effect of the new Covid19 - UK & South Africa mutations on the action of vaccines and on the binding of the virus to ACE2, so Micar21 decided to calculate pro-bono and support science worldwide. On 16.12.2020 - Micar21 starts insilico calculations. On 26.12.2020 - first version of our science publication - with calculation for English mutation COVID19. On 31.12.2020 - second version of our science publication - with calculation for South African mutation COVID19 is included and we published our scientific publication: https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2.article-metrics Dr. Filip Fratev (Micar21) is the sole author of the science publication. In less than 5 months there are already 22 citations (very good result). Our competitors appeared with insilico data for Covid19 Mutations at the end of January 2021 (can be traced through science publications) On 14.02.2021 (sent on 14.02.2021 - published on 23.02.2021) science publication by Oxford, validates Micar21 insilico results with experimental data: https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf Here, through the experimental data, our Micar21 insilico data calculated in December 2020 are proved. Micar21 predicted in silico the stronger N501Y mutant binding to ACE2 (-1.42 kcal/mol) whereas months later experimental data shown a value of (-1.40 kcal/mol), thus, confirming that our in silico results was precise. The aim of Micar21 study and new paper was to provide urgently high quality data about the effect of the UK and South African mutations. However, during the process of revision of the paper many experimental studies became available which was an excellent opportunity for a validation of the in silico approaches employed here and in particular protein-protein FEP. Also, we can compare our results to other data obtained by theoretical approaches which can be viewed and validated through other science publications and showed in our new science publication in Journal of Chemical Information and Modelling - under final review: http://micar21.com/Covid19_UK_SA_mutation.pdf

We are the developer of an innovative technology for the production of a completely new highly effective active substance. These regenerating products are extremely effective in treatment of liver cirrhosis of various etiologies previously officially considered incurable (ascites goes away after 15 days, cirrhosis changes into fibrosis after 30-50 days, the period of complete hepatic regeneration is about 4 months). They are also effective against genital herpes virus (4-6 months), effective against hepatitis of various etiologies, including such as B, C, D ( viral load is reduced by half every 26 days, after a course of therapy, the virus is not detected in the blood, the patient ceases to be a virus carrier), drugs restore the liver in case of fatty hepatosis, pulmonary tuberculosis including MDR TB/ XDR TB (after 26 days an active form of stage 4 changes into stage 2-3 of latent form), lymphosarcoma, fibroma, myoma and pyelonephritis. The drugs prevent diabetic foot gangrene extremities. After the therapy patients no longer need previously recommended heart bypass surgery. The drug restores the function of the pancreas, and gives a complete restoration of long-term erectile dysfunction. The condition of patients with Alzheimer disease, Down's syndrome, encephalopathy, encephalitis and other diseases improves significantly without any side effects. The drugs have a strong antifibrotic effect, they dissolve scars on heart after myocardial infarction. Heart tissue completely regenerates within 6 months. This is only what we have studied so far.  We have strong assumptions that our medications can also effectively affect the activity of the COVID-19 coronavirus, as well as other viruses and infections. We are interested in partners and research of our drugs.

Consulting / Advisory Services areas: • Big Data Strategy design • Analytics Applications’ roadmap design • Wider Analytics technology infrastructure architectural design and implementation • Analytics’ neighboring domains roadmap design, i.e. Loyalty Scheme design and implementation, Marketing Automation/Campaign Management systems, Mobile Applications’ hosting/integrating technologies, … Professional Implementation Services Generic Analytics Applications & Methodologies: • Value-based Segmentation or/and RFM Analysis • Behavioral Segmentation Analysis • Strategic Segmentation Analysis • Next Best Offer Analysis • Cross/Up/Deep-Selling Propensity Modeling • Early Warnings on Signs of Customers’ Defection Analysis • Anti-Attrition / Churn Propensity Modeling • Social Network Analysis (SNA) • Forecasting Analysis • Credit Risk Modeling (PD, LGD, …) • Pre-Collections & Collections Modeling Industry-specific Analytical Solutions: • Total Enterprise Streamlined Customer Management for Next Best Action (NBA) • Performance Forecasting & Distribution Network Target Allocation • Customer Lending Optimization (CLO) • Geolocation Analytics for Cards’ transactions’ boosting, penetrating loyalty partners’ network (merchants) • Customer “Digitalization” Solution • Customer Onboarding Strategy Solution • Complaints Management via Text Analytics • Streamlined solution for IFRS9 Risk Regulatory Framework compliance and overall processes management.